Tsujioka Takayuki, Wada Hideho, Yata Kenichiro, Suemori Sinichiro, Yamada Osamu, Sugihara Takashi
Division of Hematology, Department of Medicine, Kawasaki Medical School.
Rinsho Ketsueki. 2003 Jul;44(7):474-6.
A 69-year-old man was diagnosed as having acute promyelocytic leukemia (APL) and was treated with all-trans retinoic acid (ATRA) and idarubicin plus cytarabine. He achieved cytogenetic complete remission (CCR). Relapse occurred 1 year after CCR. Treatment with Am80 gave him a second CCR. However, a second relapse occurred. Re-induction therapy with ATRA was started at 70 mg per day. On day 14, abdominal fullness rapidly increased and massive ascites appeared as a symptom of retinoic acid syndrome (RAS). We ceased the ATRA treatment and started administration of methylprednisolone. The ascites decreased, but an increase of ascites was recognized again temporarily after having re-started ATRA treatment. Thus we gradually increased ATRA administration from 40 mg/day to 70 mg/day of ATRA. RAS did not occur and the patient achieved a third CCR. This case indicates that a gradual increase in ATRA administration is beneficial for RAS occurring in APL patients.
一名69岁男性被诊断为急性早幼粒细胞白血病(APL),接受全反式维甲酸(ATRA)及去甲氧柔红霉素加阿糖胞苷治疗。他达到了细胞遗传学完全缓解(CCR)。CCR 1年后复发。使用Am80治疗使他再次获得CCR。然而,再次复发。开始以每天70毫克的剂量进行ATRA再诱导治疗。第14天,腹胀迅速加重,出现大量腹水,这是维甲酸综合征(RAS)的症状。我们停止了ATRA治疗并开始给予甲泼尼龙。腹水减少,但重新开始ATRA治疗后腹水又暂时再次增多。因此我们将ATRA给药量从每天40毫克逐渐增加至70毫克。未发生RAS,患者获得了第三次CCR。该病例表明,逐渐增加ATRA给药量对APL患者发生的RAS有益。